Le Lézard
Classified in: Health, Science and technology
Subject: TRADE SHOWS/SEMINARS/WEBINARS

Aptose Biosciences to Present at Canaccord Genuity 38th Annual Growth Conference


SAN DIEGO and TORONTO, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that William G. Rice, Chairman, Ph.D., President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at the Canaccord Genuity 38th Annual Growth Conference being held from Wednesday, August 8th to Thursday, August 9th, 2018, at the Intercontinental Hotel, Boston, MA.

Dr. Rice will provide a corporate overview of the Company's recent activities and strategic direction.

Time:12:30 p.m. ET
Date:Thursday, August 9, 2018
Location:Intercontinental Hotel, Boston, MA

A live webcast of the Aptose presentation will be accessible by visiting:

http://wsw.com/webcast/canaccord30/apto/

The webcast will be archived shortly after the live event and will be available for 90 days through the Aptose website at www.aptose.com

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. APTO-253, the only clinical stage agent that directly targets the MYC oncogene and inhibits its expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or high risk MDS. CG-806 is an oral, first-in-class pan-FLT3/pan-BTK multi-cluster kinase inhibitor expected to reach IND submission by the end of 2018 and is planned for development to treat AML and certain B cell malignancies. For further information, please visit www.aptose.com.

For further information, please contact:

Aptose Biosciences
Greg Chow, CFO
647-479-9828
[email protected]

SMP Communications
Susan Pietropaolo
201-923-2049
[email protected]		 LifeSci Advisors
Michael Wood
Managing Director
646-597-6983
[email protected]


These press releases may also interest you

at 09:20
Coronis Health to Lead Discussion at Executive War College 2024
Coronis Health, a trusted partner for laboratory and pathology revenue cycle management (RCM), will be a leading voice at the upcoming Executive War College (EWC) 2024 conference from April 30 to May 1 in New Orleans. As the premier forum for...

at 09:18
PRUVN Reveals Human Clinical Trial Results of Max International's RiboCeinetm Supplementation's Impact on Serum Glutathione Levels
PRUVN Research LLC, [PRUVN], a leading research organization validating wellness products and services, is excited to announce the results of its recent preliminary study with Max International, investigating the impact of RiboCeinetm supplementation...

at 09:15
Rutgers Dual Degree program enabled graduate student to pursue interest in healthcare while she earned an MBA
After graduating from Cornell University, Daphni Sawyer worked in healthcare for more than two years before she decided to pursue an advanced degree. In May, she will graduate with two master's degrees from Rutgers. ...

at 09:15
Thirty Madison's Nurx and Cove partner with Talkspace to expand mental health support for more than half a million women
Thirty Madison, the specialty telemedicine company operating Keeps, Cove, and Nurx, today announced a partnership with Talkspace, a  leading online behavioral health company, to expand comprehensive mental health offerings for more than half a...

at 09:15
RevOpsis Secures $16.5 Million Seed Funding to Advance First-in-Class Tri-Specific Therapy for Neovascular AMD Treatment
RevOpsis Therapeutics, a next-generation biopharmaceutical company spearheading innovation in ophthalmic therapies, announced today it has successfully closed its first seed funding round, raising $16.5 million to propel its mission to develop and...

at 09:15
Evive Brands Recognized Among FranServe's FRAN-TASTIC 500 for Outstanding Franchise Opportunities
Evive Brands, a leading name in the health and home services sector, announced today that all four of its flagship brands have been named to FranServe's  FRAN-TASTIC 500 list....

More news about Health...


News published on and distributed by: